FDA
-
-
-
-
-
-
-
Mizuho Reiterates Outperform Rating on Corbus Pharmaceuticals (CRBP)
-
-
-
-
-
-
-
Corbus Pharmaceuticals (CRBP) PT Lowered to $50 at H.C. Wainwright
-
-
-
-
-
-
-
Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting
-
-
-
-
-
-
-
Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO GU
-
-
-
-
-
-
-
Akari Therapeutcis (AKTX) Appoints Rachelle Jacques as President and CEO
-
-
-
-
-
-
-
Corbus Pharmaceuticals Announces Topline Results from DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis
-
-
-
-
-
-
-
Corbus Pharmaceuticals Reports Last Subject Visit in DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

